Clinical Trials
50 trialsGemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
M.D. Anderson Cancer Center
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
Hansoh BioMedical R&D Company
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
Wake Forest University Health Sciences
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Washington University School of Medicine
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Amgen
PRESERVE-001
OncoC4, Inc.
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma
Boehringer Ingelheim
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Sarcoma Oncology Research Center, LLC
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
ImmunityBio, Inc.
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma
Eli Lilly and Company
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
GemTax
University of Pittsburgh
ANNOUNCE 2
Eli Lilly and Company
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Medical University of South Carolina
SOURCE
Morphotek
OsteoREC2015
Italian Sarcoma Group
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
GOG Foundation
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
University of Iowa
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Memorial Sloan Kettering Cancer Center
TAUL
Mario Negri Institute for Pharmacological Research
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Masonic Cancer Center, University of Minnesota
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
GOG Foundation
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
UNICANCER
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
University of Vermont
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma
University of Michigan Rogel Cancer Center
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
New Mexico Cancer Research Alliance
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Sarcoma Alliance for Research through Collaboration
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
National Cancer Center, Korea
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
GOG Foundation
STS
National Health Research Institutes, Taiwan
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma
ChineseAMS
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Docetaxel in Treating Children With Recurrent Solid Tumors
National Cancer Institute (NCI)
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Emory University
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Sarcoma Alliance for Research through Collaboration
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
Asan Medical Center
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center